These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 26628333)

  • 1. A novel injectable phospholipid gel co-loaded with doxorubicin and bromotetrandrine for resistant breast cancer treatment by intratumoral injection.
    Luo JW; Zhang T; Zhang Q; Cao X; Zeng X; Fu Y; Zhang ZR; Gong T
    Colloids Surf B Biointerfaces; 2016 Apr; 140():538-547. PubMed ID: 26628333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coencapsulated doxorubicin and bromotetrandrine lipid nanoemulsions in reversing multidrug resistance in breast cancer in vitro and in vivo.
    Cao X; Luo J; Gong T; Zhang ZR; Sun X; Fu Y
    Mol Pharm; 2015 Jan; 12(1):274-86. PubMed ID: 25469833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel doxorubicin-loaded in situ forming gel based high concentration of phospholipid for intratumoral drug delivery.
    Wu W; Chen H; Shan F; Zhou J; Sun X; Zhang L; Gong T
    Mol Pharm; 2014 Oct; 11(10):3378-85. PubMed ID: 24735404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
    Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
    Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Micelles of d-α-Tocopheryl Polyethylene Glycol 2000 Succinate (TPGS 2K) for Doxorubicin Delivery with Reversal of Multidrug Resistance.
    Hao T; Chen D; Liu K; Qi Y; Tian Y; Sun P; Liu Y; Li Z
    ACS Appl Mater Interfaces; 2015 Aug; 7(32):18064-75. PubMed ID: 26214761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-Assembled Indomethacin Dimer Nanoparticles Loaded with Doxorubicin for Combination Therapy in Resistant Breast Cancer.
    Wang X; Cheng X; He L; Zeng X; Zheng Y; Tang R
    ACS Appl Mater Interfaces; 2019 Aug; 11(32):28597-28609. PubMed ID: 31314480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic anti-tumor activity through combinational intratumoral injection of an in-situ injectable drug depot.
    Kim DY; Kwon DY; Kwon JS; Park JH; Park SH; Oh HJ; Kim JH; Min BH; Park K; Kim MS
    Biomaterials; 2016 Apr; 85():232-45. PubMed ID: 26874285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
    Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
    Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo efficacy of an intratumorally injected in situ-forming doxorubicin/poly(ethylene glycol)-b-polycaprolactone diblock copolymer.
    Kang YM; Kim GH; Kim JI; Kim DY; Lee BN; Yoon SM; Kim JH; Kim MS
    Biomaterials; 2011 Jul; 32(20):4556-64. PubMed ID: 21440935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quercetin and doxorubicin co-encapsulated biotin receptor-targeting nanoparticles for minimizing drug resistance in breast cancer.
    Lv L; Liu C; Chen C; Yu X; Chen G; Shi Y; Qin F; Ou J; Qiu K; Li G
    Oncotarget; 2016 May; 7(22):32184-99. PubMed ID: 27058756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chitosan-alginate BSA-gel-capsules for local chemotherapy against drug-resistant breast cancer.
    Shen H; Li F; Wang D; Yang Z; Yao C; Ye Y; Wang X
    Drug Des Devel Ther; 2018; 12():921-934. PubMed ID: 29719378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles.
    Yu P; Yu H; Guo C; Cui Z; Chen X; Yin Q; Zhang P; Yang X; Cui H; Li Y
    Acta Biomater; 2015 Mar; 14():115-24. PubMed ID: 25498306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy.
    Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB
    Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer.
    Sheng Y; You Y; Chen Y
    Int J Pharm; 2016 Oct; 512(1):1-13. PubMed ID: 27521706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells.
    Chakravarty G; Mathur A; Mallade P; Gerlach S; Willis J; Datta A; Srivastav S; Abdel-Mageed AB; Mondal D
    Biochimie; 2016 May; 124():53-64. PubMed ID: 26844637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
    Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
    Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment.
    Cui T; Zhang S; Sun H
    Oncol Rep; 2017 Feb; 37(2):1253-1260. PubMed ID: 28075466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen guided liposomes for targeting encapsulated anticancer agent to estrogen receptor positive breast cancer cells: in vitro and in vivo evaluation.
    Jain AS; Goel PN; Shah SM; Dhawan VV; Nikam Y; Gude RP; Nagarsenker MS
    Biomed Pharmacother; 2014 May; 68(4):429-38. PubMed ID: 24721327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of doxorubicin resistance by guggulsterone of Commiphora mukul in vivo.
    Xu HB; Shen ZL; Fu J; Xu LZ
    Phytomedicine; 2014 Sep; 21(11):1221-9. PubMed ID: 25172783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.